Status:
COMPLETED
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
Oncology/Hematology West
Conditions:
Head and Neck Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a study for patients who have head and neck cancer that has recurred in the body area where they previously received radiation, and for whom surgery is not planned. A widely accepted treatment...
Eligibility Criteria
Inclusion
- Pathologically (histologically or cytologically) confirmed diagnosis of recurrent or second primary head and neck squamous cell carcinoma (HNSCC) in patients with past history of definitive radiation therapy for head and neck cancer. Patients in whom the initial diagnosis was neck metastasis with suspected occult primary in the head and neck will be eligible.
- Patients with histologic variants such as spindle cell carcinoma, poorly-differentiated keratin positive carcinoma, and lymphoepithelioma will be eligible.
- Patients may be eligible if they have unresected recurrent disease in the prior radiation field. Patients also may be eligible if they have undergone surgical resection of recurrent disease in the prior radiation field with any of the following poor risk pathologic features:
- Malignant involvement of 2 or more regional lymph nodes
- Extracapsular extension of nodal disease
- Microscopically involved mucosal margins of resection (at 5 mM or less)
- Perineural involvement
- Resected soft tissue disease
- Oral cavity or oropharyngeal primaries with nodal disease at levels IV or V
- Patients must have had prior radiation for head and neck cancer with ≥ 50 % of the recurrent tumor within areas that have been radiated to at least 45 Gy, but not exceeding 72 Gy.
- Greater than 6 month interval from prior external beam radiation treatment. (Patients who have received intra-operative radiation therapy \[IORT\] within 6 months of registration may be eligible, if there has been no subsequent disease recurrence in the IORT field and criteria for eligibility are otherwise met).
- KPS \> or = to 70%
- Age \> or = to 18years
- Adequate bone marrow function: ANC \> or = to 1,500/μl, platelets \> or = to 100,000/μl, Hgb \> or = to 8 g/dL.
- Adequate hepatic function.
- Women of childbearing potential must have a negative pregnancy test.
- Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least three months thereafter.
- Patient must sign an informed consent document.
Exclusion
- Anticipated lifetime spinal cord dose exceeding 54 Gy, brain stem exceeding 65 Gy, optic chiasm exceeding 55 Gy, and optic nerves exceeding 60 Gy.
- Three or more palliative cytotoxic chemotherapy regimens in the recurrent or metastatic disease setting.
- Pregnancy or lactation.
- Distant metastatic disease.
- Other active malignancy, other than indolent malignancies which the investigator determines are unlikely to interfere with treatment or efficacy analysis. For example, patients with nonmelanoma skin cancer, in situ carcinoma of the cervix, or prostate cancer within the no current biochemical (PSA) or radiologic evidence of disease may enroll.
- Serious concomitant medical disorders (for example, active infection, uncontrolled seizure disorder, unstable angina) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study.
- History of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate-80.
- History of severe infusion reaction to a monoclonal antibody.
- Patients with multifocal peripheral sensory alterations or paresthesias (including tingling) interfering with function, per patient report (example: activities of daily living).
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00713219
Start Date
July 1 2008
End Date
April 1 2013
Last Update
April 23 2015
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology/Hematology West
Omaha, Nebraska, United States, 68114
2
Memorial Sloan-Kettering Cancer Center at Basking Ridge
Basking Ridge, New Jersey, United States, 07939
3
Memorial Sloan-Kettering Cancer Center at Commack
Commack, New York, United States, 11725
4
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065